Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PDGFRB |
| Variant | I535_A540delinsVPSWP |
| Impact List | indel |
| Protein Effect | gain of function |
| Gene Variant Descriptions | PDGFRB I535_A540delinsVPSWP results in a deletion of six amino acids in the cytoplasmic domain of the Pdgfrb protein from amino acids 535 to 540, combined with the insertion of five amino acids at the same site (UniProt.org). I535_A540delinsVPSWP confers a gain of function to the Pdgfrb protein as indicated by constitutive phosphorylation of Pdgfrb and phosphorylation of Stat3 in cultured cells, and activation of the Stat and Mapk pathways in the absence of ligand in a reporter assay (PMID: 36201717). |
| Associated Drug Resistance | |
| Category Variants Paths |
PDGFRB mutant PDGFRB act mut PDGFRB I535_A540delinsVPSWP |
| Transcript | NM_002609.4 |
| gDNA | chr5:g.150126574_150126591delinsAGGCCAGCTAGGTAC |
| cDNA | c.1603_1620delinsGTACCTAGCTGGCCT |
| Protein | p.I535_A540delinsVPSWP |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002609.4 | chr5:g.150126574_150126591delinsAGGCCAGCTAGGTAC | c.1603_1620delinsGTACCTAGCTGGCCT | p.I535_A540delinsVPSWP | RefSeq | GRCh38/hg38 |
| NM_002609.3 | chr5:g.150126574_150126591delinsAGGCCAGCTAGGTAC | c.1603_1620delinsGTACCTAGCTGGCCT | p.I535_A540delinsVPSWP | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PDGFRB I535_A540delinsVPSWP | infantile myofibromatosis | predicted - sensitive | Imatinib | Case Reports/Case Series | Actionable | In a clinical case study, Gleevec (imatinib) treatment resulted in improvement in the small bowel obstruction and gastric myofibromas after 6 weeks in a patient with multicentric infantile myofibromatosis harboring PDGFRB I535_A540delinsVPSWP, and in a preclinical analysis, Gleevec (imatinib) inhibited STAT and MAPK pathway activity in cells expressing PDGFRB I535_A540delinsVPSWP in a luciferase assay (PMID: 36201717). | 36201717 |